ANTICIPATE Study Recruits All 1000 Patients

At 6 PM on October 20^th, patient number 1000 was enrolled in COMBACTE-NET’s ANTICIPATE study. This concludes the study’s 1000-patient milestone. The 1000 eligible patients have been included over a 13 months’ period.

Fighting against C. difficile infections

ANTICIPATE is an observational, epidemiological study involving hospitalized patients undergoing oral or intravenous broad-spectrum antibiotics treatments. The study aims to determine the incidence of Clostridium difficile infections and to better prevent this severe pathology. It is being conducted in close collaboration with Da Volterra – ANTICIPATE’s EFPIA Lead.

Clinical development of DAV132

DAV132 is Da Volterra’s promising new therapeutic agent for the prevention of Clostridium difficile infections in high-risk patients. It is currently in the stage of clinical development. The product protects the intestinal microbiota from antibiotics-induced alterations. ANTICIPATE aims to accelerate that development, optimally preparing for a Phase III trial with DAV132.

Recruitment milestone

The team is delighted to have reached this important milestone and is very thankful to all the sites and the patients for their commitment and efforts. All 34 sites in the ANTICIPATE study enrolled patients, without any single non-performing site.

The top enrolling sites are:

1. Hospital Universitario Reina Sofia, Spain: 160 inclusions
2. Hospital Universitario Virgen Macarena, Spain: 99 inclusions
3. Oncology Institute Ion Chiricuta Cluj Napoca, Romania: 93 inclusions
4. UKK Uniklinik Köln, Germany: 83 inclusions
5. CHU Tours, France: 80 inclusions

The ANTICIPATE study has a 90-day follow up period. The Patient Last Visit will take place mid-January 2018. The team’s focus will now be on patient retention and query resolution in order to meet the ambitious timelines of database closure.